Using Atorvastatin to Treat Ulcerative Colitis
Combination of Atorvastatin and Mesalazine to Enhance Anti-inflammatory Effects and Attenuates Progression of Ulcerative Colitis
This study is testing if atorvastatin, a cholesterol-lowering medication, can help adults with ulcerative colitis feel better by reducing inflammation.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Tanta University Academic / other |
| Locations | 1 site (Mansoura) |
| Trial ID | NCT05561062 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effects of atorvastatin, a medication commonly used to lower cholesterol, on patients with ulcerative colitis, a chronic inflammatory bowel disease. The study aims to explore atorvastatin's potential anti-inflammatory and immunomodulatory properties that may benefit individuals suffering from this condition. Participants will receive an 80mg dose of atorvastatin, and the trial will assess its efficacy and safety in managing ulcerative colitis symptoms. The study is designed for adults aged 18 and older, excluding those with severe disease or certain other health conditions.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older diagnosed with ulcerative colitis who meet the inclusion criteria.
Not a fit: Patients with severe ulcerative colitis or those on specific immunosuppressive therapies may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a new therapeutic option for managing ulcerative colitis symptoms and improving patient quality of life.
How similar studies have performed: While the use of atorvastatin in ulcerative colitis is a novel approach, other studies have explored statins for inflammatory conditions with varying degrees of success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Both male and female will be included * Negative pregnancy test and effective contraception Exclusion Criteria: * Breastfeeding * Significant liver and kidney function abnormalities * Colorectal cancer patients * Patients with severe UC * Patients taking rectal or systemic steroids * Patients taking immunosuppressives or biological therapies
Where this trial is running
Mansoura
- Faculty of Medicine, Mansoura University — Mansoura, Egypt (Recruiting)
Study contacts
- Study coordinator: Mostafa Bahaa, PhD
- Email: mbahaa@horus.edu.eg
- Phone: 0201025538337
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.